News beyond our pages

As-needed budesonide-formoterol has been shown to prevent severe exacerbations in patients with mild asthma compared with as-needed use of a short-acting b2-agonist, such as albuterol, in tightly controlled clinical trials. Beasley et al (N Engl J Med 2019;380:2020-30; https://doi.org/10.1056/NEJMoa1901963) reproduced this finding in an open-label randomized trial (START) that better mimicked clinical practice. Use of as-needed budesonide-formoterol decreased the annualized rate of all exacerbations, as well as that of severe exacerbations specifically, compared with as-needed albuterol and was also superior to maintenance budesonide plus as-needed albuterol for severe exacerbations.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Tags: News beyond our pages Source Type: research